Glatiramer Acetate in Multiple Sclerosis: A Review

Wiley - Tập 13 Số 2 - Trang 178-191 - 2007
Maddalena Ruggieri1, Carlo Avolio2, Paolo Livrea1, María Trojano1
1Dept. of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy
2Department of Medical and Occupational Sciences, University of Foggia, Foggia, Italy

Tóm tắt

ABSTRACTMultiple sclerosis (MS) is considered to be primarily an inflammatory autoimmune disease. Over the last 5 years, our view of the pathogenesis of MS has evolved considerably. The axonal damage was recognized as an early event in the disease process and as an important determinant of long‐term disability. Therefore, the antiinflammatory and neuroprotective strategies are thought to represent promising approach to the therapy of MS. The therapeutic potential of glatiramer acetate (GA), a synthetic amino acid polymer composed of a mixture of l‐glutamic acid, l‐lysine, l‐alanine, and l‐tyrosine in defined proportions, in MS has been apparent for many years. GA has been shown to be effective in preventing and suppressing experimental allergic encephalomyelitis (EAE), the animal model of MS. GA has been, therefore, evaluated in several clinical studies and found to alter the natural history of relapsing‐remitting (RR)MS by reducing the relapse rate and affecting disability. These findings were confirmed in open‐label follow‐up trials covering more than 10 years of treatment. The trials demonstrated sustained efficacy for GA in slowing the progression of disability. The clinical therapeutic effect of GA is consistent with the results of magnetic resonance imaging (MRI) findings from various clinical centers. At a daily standard dose of 20 mg, s.c., GA was generally well tolerated. The induction of GA‐reactive T‐helper 2‐like regulatory suppressor cells is thought to be the main mechanism of the therapeutic action of this drug. In addition, it was recently shown that GA‐reactive T cells produce neurotrophic factors (e.g., brain‐derived neurotrophic factor [BDNF]) that protect neurons and axons in the area of injury.

Từ khóa


Tài liệu tham khảo

10.1073/pnas.0509438102

10.1073/pnas.2336171100

10.1016/S0165-2478(97)00032-1

10.1073/pnas.94.20.10821

10.1016/S0165-5728(98)00166-0

10.1073/pnas.96.2.634

10.1073/pnas.97.21.11472

10.1034/j.1600-0404.2001.00125.x

10.1007/BF00873697

10.1191/1352458503ms932oa

10.1056/NEJM198708133170703

10.1016/S0165-5728(01)00250-8

10.1016/S0022-510X(03)00177-1

Chen M, 2001, Glatiramer acetate induces a Th2‐biased response and cross reactivity with myelin basic protein in patients with MS, MultScler 7, 209

Cohen J, 2006, Results of a randomized, double‐blind, parallel‐group study assessing safety and efficacy of 40 mg versus 20 mg of glatiramer acetate on MRI‐measured disease activity in RRMS, Neurology, 66, S61

10.1002/ana.64

10.1016/S0140-6736(02)08220-X

10.1093/brain/121.8.1469

10.1212/WNL.58.8_suppl_4.S3

10.1016/j.jneuroim.2006.07.014

10.4049/jimmunol.165.12.7300

10.1172/JCI8970

10.1093/brain/124.4.705

10.1016/S1474-4422(06)70327-1

10.1191/135248506ms1318oa

10.1093/intimm/9.7.925

10.1016/S0168-0102(03)00217-7

10.1212/WNL.55.11.1704

10.1172/JCI0215198

10.1098/rstb.1999.0513

10.1212/WNL.50.3.701

10.1212/WNL.45.7.1268

10.1177/135245850000600407

10.1191/1352458503ms961oa

10.1111/j.1600-0404.2004.00351.x

10.1191/1352458505ms1234oa

10.1016/0022-510X(79)90058-3

10.1073/pnas.97.13.7446

10.1146/annurev.immunol.17.1.221

10.1212/WNL.50.4.1127

10.1016/S0165-5728(98)00191-X

10.1016/0165-5728(95)00085-G

Munari L, 2004, Therapy with glatiramer acetate for multiple sclerosis, Cochrane Database Syst Rev, 1

10.1073/pnas.97.13.7452

10.1056/NEJM200009283431307

10.1016/S0140-6736(05)60642-3

10.1016/S0165-5728(00)00263-0

10.1007/s00415-006-0178-z

10.1159/000073860

10.1007/s00415-005-0965-y

10.1517/14656566.2.7.1149

10.3109/08830189909043025

10.1016/S0165-5728(02)00024-3

10.1016/S0165-5728(02)00400-9

10.1172/JCI25805

10.1007/PL00000576

10.1016/0165-5728(95)00180-8

10.1002/eji.1830010406

10.1073/pnas.89.1.137

10.1016/0090-1229(74)90012-9

10.1096/fj.01-1023fje

10.1126/science.280.5361.243

Vollmer T, 2006, Short‐term induction with mitoxantrone preceding treatment with glatiramer acetate offers early and pronounced effects on MRI‐disease activity in patients with relapsing forms of multiple sclerosis, Mult Scler, 12, S11

10.1093/brain/awh163

10.1002/ana.21079

10.1093/brain/awf252

Ziemssen T, 2002, Glatiramer acetate‐specific T cell lines produce brain‐derived neurotrophic factor (BDNF) after activation upon antigen challenge in vitro: A novel mechanism of action?, Neurology, 58, A326

10.2165/00002018-200124130-00005

10.1007/s004410000179

10.1016/S0167-5699(99)01545-5

Thông tin
Thông tin xuất bản

Wiley

Tập 13 Số 2

178-191

Thông tin tác giả